Your browser doesn't support javascript.
loading
Beneficial effects of botulinum toxin type A in trigeminal neuralgia / Beneficio de la toxina botulínica tipo A en neuralgia del trigemino
Zúñiga, Carlos; Díaz, Sergio; Piedimonte, Fabián; Micheli, Federico.
Affiliation
  • Zúñiga, Carlos; Hospital de Clínicas José de San Martín. Parkinson's Disease and Movement Disorders Unit. Buenos Aires. AR
  • Díaz, Sergio; Hospital de Clínicas José de San Martín. Parkinson's Disease and Movement Disorders Unit. Buenos Aires. AR
  • Piedimonte, Fabián; Hospital de Clínicas José de San Martín. Parkinson's Disease and Movement Disorders Unit. Buenos Aires. AR
  • Micheli, Federico; Hospital de Clínicas José de San Martín. Parkinson's Disease and Movement Disorders Unit. Buenos Aires. AR
Arq. neuropsiquiatr ; Arq. neuropsiquiatr;66(3a): 500-503, set. 2008. tab
Article in En | LILACS | ID: lil-492570
Responsible library: BR1.1
ABSTRACT
Botulinum toxin has been thoroughly studied as a potential tool in the treatment of several pain syndromes. Therefore, we assessed the clinical effects of botulinum toxin type A injections in 12 patients with otherwise unresponsive idiopathic trigeminal neuralgia. Patients were infiltrated with 20-50 units of botulinum toxin in trigger zones. Those who presented with mandibular involvement were also infiltrated in the masseter muscle. The patients were assessed on a weekly basis using the Visual Analogic Scale for pain. Ten of our patients reported a significant benefit from botulinum toxin injections, with reduction or even disappearance of pain, and remained pain free for as long as 60 days. Our findings suggest that botulinum toxin may represent a useful therapeutic tool in the management of patients with this entity.
RESUMEN
La toxina botulínica ha sido estudiada en forma exhaustiva como una potencial herramienta en el tratamiento de múltiples síndromes dolorosos. Por lo tanto, evaluamos los efectos clínicos de la aplicación de toxina botulínica tipo A en 12 sujetos con neuralgia trigeminal idiopática resistente a manejo farmacológico. Se aplicaron en dichos sujetos entre 20 y 50 unidades de toxina botulínica tipo A en las zonas gatillo. Además se infiltró el músculo masetero en aquellos que presentaban involucro mandibular. Los sujetos fueron evaluados semanalmente con una escala visual análoga para dolor. Diez de los sujetos reportaron un beneficio significativo con el uso de toxina botulínica, con reducción e incluso desaparición del dolor, permaneciendo libres de dolor por un periodo de hasta 60 días. Nuestros hallazgos sugieren que la toxina botulínica puede representar una herramienta terapéutica útil en el manejo de pacientes con esta entidad.
Subject(s)
Key words
Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Trigeminal Neuralgia / Facial Pain / Botulinum Toxins, Type A / Analgesics / Neuromuscular Agents Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male Language: En Journal: Arq. neuropsiquiatr Journal subject: NEUROLOGIA / PSIQUIATRIA Year: 2008 Document type: Article Affiliation country: Argentina Country of publication: Brazil
Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Trigeminal Neuralgia / Facial Pain / Botulinum Toxins, Type A / Analgesics / Neuromuscular Agents Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male Language: En Journal: Arq. neuropsiquiatr Journal subject: NEUROLOGIA / PSIQUIATRIA Year: 2008 Document type: Article Affiliation country: Argentina Country of publication: Brazil